ArriVent BioPharma (NASDAQ:AVBP) Issues Earnings Results

ArriVent BioPharma (NASDAQ:AVBP) posted its quarterly earnings data on Thursday. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.09, FiscalAI reports.

ArriVent BioPharma Stock Down 7.2%

Shares of AVBP stock traded down $1.82 during trading hours on Friday, reaching $23.43. The company’s stock had a trading volume of 1,788,119 shares, compared to its average volume of 478,779. ArriVent BioPharma has a fifty-two week low of $15.47 and a fifty-two week high of $27.22. The firm’s 50 day simple moving average is $22.17 and its 200-day simple moving average is $20.89. The company has a market capitalization of $967.19 million, a price-to-earnings ratio of -5.53 and a beta of 0.99.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Zacks Research upgraded shares of ArriVent BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, December 5th. Citigroup raised their target price on shares of ArriVent BioPharma from $31.00 to $33.00 and gave the stock a “buy” rating in a report on Friday. Cantor Fitzgerald started coverage on shares of ArriVent BioPharma in a research report on Monday, December 22nd. They issued an “overweight” rating for the company. Oppenheimer reissued an “outperform” rating and set a $50.00 price target (up from $44.00) on shares of ArriVent BioPharma in a research report on Friday. Finally, BTIG Research started coverage on ArriVent BioPharma in a research note on Wednesday, December 10th. They set a “buy” rating and a $45.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $41.11.

Institutional Trading of ArriVent BioPharma

Several large investors have recently bought and sold shares of the business. Infinitum Asset Management LLC raised its stake in shares of ArriVent BioPharma by 6.6% during the fourth quarter. Infinitum Asset Management LLC now owns 4,123,923 shares of the company’s stock valued at $82,973,000 after acquiring an additional 255,000 shares during the last quarter. Suvretta Capital Management LLC increased its holdings in ArriVent BioPharma by 10.9% in the fourth quarter. Suvretta Capital Management LLC now owns 4,106,035 shares of the company’s stock valued at $82,613,000 after purchasing an additional 402,583 shares during the period. Vanguard Group Inc. raised its position in ArriVent BioPharma by 36.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,029,531 shares of the company’s stock worth $37,445,000 after purchasing an additional 545,991 shares during the last quarter. State Street Corp raised its position in ArriVent BioPharma by 6.3% during the 4th quarter. State Street Corp now owns 1,091,980 shares of the company’s stock worth $21,971,000 after purchasing an additional 64,352 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in ArriVent BioPharma by 5.2% during the 4th quarter. Geode Capital Management LLC now owns 753,519 shares of the company’s stock worth $15,164,000 after buying an additional 37,231 shares during the period. 9.48% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about ArriVent BioPharma

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: Multiple analyst upgrades and price-target raises: Oppenheimer reaffirmed an “outperform” and raised its price target to $50 (from $44), implying a very large upside from current levels. HC Wainwright raised its target to $44 (from $42) with a “buy” rating, and Citigroup lifted its target to $33 (from $31) and maintains a “buy.” These upgrades increase analyst-driven upside expectations and likely attracted buyer interest earlier in the session. Oppenheimer/TickerReport
• Positive Sentiment: Unusually heavy call-option buying: Traders bought ~1,832 call contracts (≈321% above typical volume), a clear sign that some market participants are positioning for an upside move. Elevated call activity can amplify intraday volatility and signal bullish sentiment among derivatives traders.
• Positive Sentiment: Quarterly earnings slightly beat expectations: AVBP reported (–$0.78) EPS, beating the consensus (–$0.87) by $0.09. A beat in a clinical‑stage biotech is a constructive data point even though EPS remains negative. Earnings press release
• Neutral Sentiment: Full‑year 2025 results & company update: The company issued its FY2025 financial results and highlighted recent progress. The release provides context on cash runway and program milestones but did not contain a major surprise that alone would drive a sustained directional move. GlobeNewswire
• Neutral Sentiment: Brokerage consensus: Aggregate broker coverage shows a “Moderate Buy” consensus, reinforcing the analyst optimism but not materially changing the story. American Banking News
• Neutral Sentiment: Short‑interest reporting anomalies: Recent short‑interest entries show 0 shares / NaN changes — likely a reporting or data issue. There’s no reliable evidence of a new short-squeeze dynamic based on the posted figures.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.